Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) went down by -3.73% from its latest closing price compared to the recent 1-year high of $40.14. The company’s stock price has collected -0.98% of loss in the last five trading sessions. Press Release reported 16 hours ago that Dicerna Announces Interim Results From Phase 1 Trial of Belcesiran for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Is It Worth Investing in Dicerna Pharmaceuticals Inc. (NASDAQ :DRNA) Right Now?
Plus, the 36-month beta value for DRNA is at 1.07. Opinions of the stock are interesting as 10 analysts out of 10 who provided ratings for Dicerna Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $42.00, which is $3.5 above the current price. DRNA currently public float of 70.53M and currently shorts hold a 5.66% ratio of that float. Today, the average trading volume of DRNA was 742.16K shares.
DRNA’s Market Performance
DRNA stocks went down by -0.98% for the week, with a monthly jump of 2.86% and a quarterly performance of 31.04%, while its annual performance rate touched 66.88%. The volatility ratio for the week stands at 5.57% while the volatility levels for the past 30 days are set at 4.65% for Dicerna Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is 1.99% for DRNA stocks with a simple moving average of 43.25% for the last 200 days.
Analysts’ Opinion of DRNA
Many brokerage firms have already submitted their reports for DRNA stocks, with Goldman repeating the rating for DRNA by listing it as a “Buy.” The predicted price for DRNA in the upcoming period, according to Goldman is $48 based on the research report published on April 16th of the current year 2021.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see DRNA reach a price target of $40, previously predicting the price at $35. The rating they have provided for DRNA stocks is “Buy” according to the report published on March 02nd, 2021.
H.C. Wainwright gave a rating of “Buy” to DRNA, setting the target price at $35 in the report published on August 07th of the previous year.
DRNA Trading at 13.83% from the 50-Day Moving Average
After a stumble in the market that brought DRNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.09% of loss for the given period.
Volatility was left at 4.65%, however, over the last 30 days, the volatility rate increased by 5.57%, as shares surge +3.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +48.65% upper at present.
During the last 5 trading sessions, DRNA fell by -0.98%, which changed the moving average for the period of 200-days by +112.94% in comparison to the 20-day moving average, which settled at $37.81. In addition, Dicerna Pharmaceuticals Inc. saw 74.76% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at DRNA starting from Weissman James B, who sale 30,000 shares at the price of $39.09 back on Jul 06. After this action, Weissman James B now owns 16,000 shares of Dicerna Pharmaceuticals Inc., valued at $1,172,700 using the latest closing price.
Brown Bob D, the Chief Scientific Ofr., EVP R&D of Dicerna Pharmaceuticals Inc., sale 8,312 shares at $37.37 during a trade that took place back on Jul 01, which means that Brown Bob D is holding 21,517 shares at $310,641 based on the most recent closing price.
Stock Fundamentals for DRNA
Current profitability levels for the company are sitting at:
- -68.90 for the present operating margin
The net margin for Dicerna Pharmaceuticals Inc. stands at -68.62. The total capital return value is set at -61.92, while invested capital returns managed to touch -62.84. Equity return is now at value -82.90, with -17.10 for asset returns.
Based on Dicerna Pharmaceuticals Inc. (DRNA), the company’s capital structure generated 37.88 points at debt to equity in total, while total debt to capital is 27.47. Total debt to assets is 7.18, with long-term debt to equity ratio resting at 35.38. Finally, the long-term debt to capital ratio is 25.66.
When we switch over and look at the enterprise to sales, we see a ratio of 6.80, with the company’s debt to enterprise value settled at 0.05. The receivables turnover for the company is 1.39 and the total asset turnover is 0.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.48.